DowpharmaSM and Cygnus Technologies, Inc. Announce Launch of Pseudomonas fluorescens Host Cell Protein Kit
Kit intended for release testing of biopharmaceuticals expressed in Pseudomonas fluorescens
Midland, MI and Southport, NC -DowpharmaSM, a business unit of The Dow Chemical Company, and Cygnus Technologies, Inc. today announced that Cygnus has launched a new kit for testing for the presence of host cell proteins in proteins expressed in Pseudomonas fluorescens.
“This new kit will enable users of Dowpharma Pfēnex Expression Technology™ to routinely test their products for the presence of host cell protein with a fully validated method,” said Charles Squires, R&D director, Dowpharma. “Cygnus Technology is the leading provider of cell protein detection kits and we are very happy that they decided to develop and launch a kit for Pseudomonas fluorescens.”
Ken Hoffman, president at Cygnus Technologies said, “More and more pharmaceutical and biotech companies have been adopting the Pfēnex Expression Technology, and we have responded to this growing need by providing a fully validated test that will satisfy the industry’s need for accurate, rapid and cost-effective QC measures.”
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.